Literature DB >> 16167067

HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis.

R N Saha1, K Pahan.   

Abstract

Gradual disclosure of the molecular basis of selective neuronal apoptosis during neurodegenerative diseases reveals active participation of acetylating and deacetylating agents during the process. Several studies have now successfully manipulated neuronal vulnerability by influencing the dose and enzymatic activity of histone acetyltransferases (HATs) and histone deacetylases (HDACs), enzymes regulating acetylation homeostasis within the nucleus, thus focusing on the importance of balanced acetylation status in neuronal vitality. It is now increasingly becoming clear that acetylation balance is greatly impaired during neurodegenerative conditions. Herein, we attempt to illuminate molecular means by which such impairment is manifested and how the compromised acetylation homeostasis is intimately coupled to neurodegeneration. Finally, we discuss the therapeutic potential of reinstating the HAT-HDAC balance to ameliorate neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16167067      PMCID: PMC1963416          DOI: 10.1038/sj.cdd.4401769

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  59 in total

1.  Antisense-mediated depletion of p300 in human cells leads to premature G1 exit and up-regulation of c-MYC.

Authors:  S Kolli; A M Buchmann; J Williams; S Weitzman; B Thimmapaya
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

Review 2.  Histone acetyltransferases: function, structure, and catalysis.

Authors:  R Marmorstein; S Y Roth
Journal:  Curr Opin Genet Dev       Date:  2001-04       Impact factor: 5.578

3.  Polyglutamine and CBP: fatal attraction?

Authors:  A McCampbell; K H Fischbeck
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

4.  Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity.

Authors:  F C Nucifora ; M Sasaki; M F Peters; H Huang; J K Cooper; M Yamada; H Takahashi; S Tsuji; J Troncoso; V L Dawson; T M Dawson; C A Ross
Journal:  Science       Date:  2001-03-23       Impact factor: 47.728

5.  Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons.

Authors:  A Riccio; S Ahn; C M Davenport; J A Blendy; D D Ginty
Journal:  Science       Date:  1999-12-17       Impact factor: 47.728

Review 6.  Transcriptional dysregulation in Huntington's disease.

Authors:  J H Cha
Journal:  Trends Neurosci       Date:  2000-09       Impact factor: 13.837

Review 7.  HIF-1 and human disease: one highly involved factor.

Authors:  G L Semenza
Journal:  Genes Dev       Date:  2000-08-15       Impact factor: 11.361

8.  Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells.

Authors:  T Davis; C Kennedy; Y E Chiew; C L Clarke; A deFazio
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

9.  Cyclic AMP response element binding protein (CREB) and CREB binding protein (CBP) in global cerebral ischemia.

Authors:  K Jin; X O Mao; R P Simon; D A Greenberg
Journal:  J Mol Neurosci       Date:  2001-02       Impact factor: 3.444

10.  Histone binding protein RbAp48 interacts with a complex of CREB binding protein and phosphorylated CREB.

Authors:  Q Zhang; N Vo; R H Goodman
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

View more
  140 in total

Review 1.  Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries.

Authors:  Na'ama A Shein; Esther Shohami
Journal:  Mol Med       Date:  2011-01-25       Impact factor: 6.354

2.  Creating a pro-survival and anti-inflammatory phenotype by modulation of acetylation in models of hemorrhagic and septic shock.

Authors:  Yongqing Li; Hasan B Alam
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 3.  Chemical biology of histone acetyltransferase natural compounds modulators.

Authors:  Fabrizio Dal Piaz; Antonio Vassallo; Osmany Cuesta Rubio; Sabrina Castellano; Gianluca Sbardella; Nunziatina De Tommasi
Journal:  Mol Divers       Date:  2011-01-01       Impact factor: 2.943

4.  Acetylation of retinal histones in diabetes increases inflammatory proteins: effects of minocycline and manipulation of histone acetyltransferase (HAT) and histone deacetylase (HDAC).

Authors:  Chandra Sekhar Rao Kadiyala; Ling Zheng; Yunpeng Du; Elizabeth Yohannes; Hung-Ying Kao; Masaru Miyagi; Timothy S Kern
Journal:  J Biol Chem       Date:  2012-05-30       Impact factor: 5.157

5.  DNA methyltransferase- and histone deacetylase-mediated epigenetic alterations induced by low-level methylmercury exposure disrupt neuronal development.

Authors:  Suzuna Go; Hisaka Kurita; Manami Hatano; Kana Matsumoto; Hina Nogawa; Masatake Fujimura; Masatoshi Inden; Isao Hozumi
Journal:  Arch Toxicol       Date:  2021-01-16       Impact factor: 5.153

6.  Histone deactylase 1 expression is increased in the prefrontal cortex of schizophrenia subjects: analysis of the National Brain Databank microarray collection.

Authors:  Rajiv P Sharma; Dennis R Grayson; David P Gavin
Journal:  Schizophr Res       Date:  2007-10-24       Impact factor: 4.939

7.  Effects of trichostatin A on neuronal mu-opioid receptor gene expression.

Authors:  Ying-Chih Lin; Kelly E Flock; Ryan J Cook; Amanda J Hunkele; Horace H Loh; Jane L Ko
Journal:  Brain Res       Date:  2008-10-11       Impact factor: 3.252

8.  Aminoglycoside-induced histone deacetylation and hair cell death in the mouse cochlea.

Authors:  Fu-Quan Chen; Jochen Schacht; Su-Hua Sha
Journal:  J Neurochem       Date:  2009-01-29       Impact factor: 5.372

9.  Dysregulation of CREB activation and histone acetylation in 3-nitropropionic acid-treated cortical neurons: prevention by BDNF and NGF.

Authors:  Sandra Almeida; Teresa Cunha-Oliveira; Mário Laço; Catarina R Oliveira; A Cristina Rego
Journal:  Neurotox Res       Date:  2009-09-25       Impact factor: 3.911

10.  Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.

Authors:  D M Vargas; M A De Bastiani; R B Parsons; F Klamt
Journal:  Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.